drugset
drugset / Trial / NCT05496465

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

NCT05496465 ↗

Phase 2 Completed 21 enrolled ARS Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

Determine the effect of ARS-1 on a patient reported pruritus/hive score

Timeline

Start
2022-07-28
Primary completion
2024-02-29
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ARS-1 Unknown 1 mg Intranasal
Subject ARS-1 Unknown 2 mg Intranasal

Indications

urticaria